Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease

September 2022, Vol 3, No 3 — September 29, 2022

Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1 A single-institution experience in treating patients with metastatic iCCA with local liver-directed radiation therapy (RT) was presented at the 2022 ASCO annual meeting.

This retrospective analysis included 67 patients with iCCA and extrahepatic metastatic disease who received RT with a biologically equivalent dose (BED) of ≥50 Gy at MD Anderson Cancer Center from January 1, 2011, to March 31, 2021. The median age was 63 years (range, 29-83 years); 52.2% of patients were men. The majority of patients (98.5%) received induction chemotherapy, most commonly gemcitabine/cisplatin (65.7%) or gemcitabine, cisplatin, paclitaxel (22.4%). Induction chemotherapy was followed by RT to the primary lesion in the liver; 71.6% received concurrent chemotherapy; the most common concurrent systemic therapy was capecitabine.

Overall, patients received a median RT dose of 60 Gy (range, 40-100 Gy), and 73.1% of patients received a BED of >80.5 Gy. A total of 43 patients had satellitosis; of these, 29 were treated with RT to the dominant liver lesion, and 14 received RT to the primary lesion and ≥1 satellite lesions. Local progression of the radiated lesion was reported in 15 (22.4%) patients; 42 (62.7%) patients progressed elsewhere in the liver, and 52 (77.6%) patients had a distant progression.

TRLF was the cause of death in 28.4% of all patients. Median freedom from TRLF (FFTRLF) was 28.2 months; the 1-year FFTRLF rate was 73.1% and the 2-year FFTRLF rate was 58.2%. Median OS from diagnosis was 25.0 months, and the median OS after RT was 11.9 months; 1-year OS after RT was 47.1% and 2-year OS after RT was 24.7%.

In a univariate analysis, no significant association of FFTRLF or OS was correlated with age, sex, performance status, size of liver lesions, tumor or node stage, satellitosis, vascular thrombosis, TRLF, timing of metastasis, site of metastasis, RT technique, or dose of chemotherapy.

The results of this single-institution study indicated that liver-directed RT was associated with favorable TRLF rates and survival times in patients with metastatic iCCA and extrahepatic disease. The authors concluded, “liver-directed radiation therapy can alter the natural history of metastatic iCCA by preventing or delaying liver failure. Future prospective studies are warranted to define the survival benefit in these patients attributable to RT.”


  1. Yamashita S, Koay EJ, Passot G, et al. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients. Cancer. 2017;123:1354-1362.

Source: Upadhyay R, Ludmir EB, De B, et al. Preservation of liver function with local radiation therapy in patients with metastatic intrahepatic cholangiocarcinoma with extrahepatic disease. Abstract 4080.

Related Items

HRQOL in Patients With Advanced BTC Who Received Pembrolizumab With GemCis in the KEYNOTE-966 study
September 2023, Vol 4, No 3
Researchers explore the impact of gemcitabine/cisplatin plus pembrolizumab on patient health-related quality of life in a subanalysis of the KEYNOTE-966 study.
Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC: The ADJUBIL Study
September 2023, Vol 4, No 3
Researchers in the ADJUBIL study plan to assess the clinical activity of the immunotherapies durvalumab and tremelimumab with or without capecitabine in patients with resectable biliary tract cancer in the adjuvant setting.
SGNTUC-019: A Phase 2 Study of Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC
September 2023, Vol 4, No 3
Basket study investigated targeted therapies as second-line treatment for patients with biliary tract cancer who are HER2-positive.
Rucaparib and Nivolumab as Maintenance Therapy Following Chemotherapy in Patients With Advanced BTC: BilT-02
September 2023, Vol 4, No 3
Researchers are investigating novel combination therapies, including immunotherapies and poly-ADP ribose polymerase (PARP) inhibitors, to improve survival in patients with biliary tract cancer; here, the BilT-02 study is summarized.
Results From HERIZON-BTC-01: Zanidatamab in Previously Treated HER2-Amplified BTC
September 2023, Vol 4, No 3
Preliminary results from the phase 2b HERIZON-BTC-01 study investigating the efficacy of zanidatamab in patients with HER2-positive biliary tract cancer are presented.
Using ctDNA as a Predictive Biomarker in Patients With CCA: Subanalysis of the STAMP Trial
September 2023, Vol 4, No 3
A subanalysis of the STAMP trial examines the clinical impact of using circulating tumor DNA for detecting molecular residual disease and monitoring in patients with CCA in the adjuvant setting.
BILCAP Investigators Explore Alterations in Cancer Driver Genes and Other Mutations in Patients With BTC
September 2023, Vol 4, No 3
The researchers found that EGFR amplifications and FGFR3 fusions may be important predictive biomarkers in biliary tract cancer (BTC) and may serve as a future target for systemic anticancer therapy in patients with BTC.
Using Liquid Biopsy to Detect FGFR2 and Other Actionable Rearrangements in Patients With GI Cancer
September 2023, Vol 4, No 3
Pashtoon Kasi, MD, MS, presented results of a study exploring the utility of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies.
CCA Summit Live from ASCO 2023
By Renuka V. Iyer, MD; Vaibhav Sahai, MBBS, MS
On June 4, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO).
GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: